SCHEDULE: L.I.A. Pure Capital Discloses 5% Stake in Clearmind Medicine

L.I.A. Pure Capital Ltd. has reported a 5.0% beneficial ownership stake in Clearmind Medicine Inc., primarily through common shares, a convertible note, and a pre-funded warrant.

Summary

• L.I.A. Pure Capital Ltd. (Reporting Person) holds 108,720 common shares of Clearmind Medicine Inc. (Issuer).
• This represents 5.0% of Clearmind Medicine Inc.'s common shares outstanding.
• The percentage is calculated based on 2,088,806 common shares issued and outstanding as of the reporting date.
• Beneficial ownership includes 20,470 existing common shares, 93,231 common shares issuable from a convertible promissory note, and 229,000 common shares issuable from a pre-funded warrant.
• Both the convertible note and pre-funded warrant contain a blocker provision limiting conversion/exercise to prevent beneficial ownership exceeding 4.99% of ordinary shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a passive investment.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it confirms a significant institutional investor's stake, but provides no new operational or financial performance data for the issuer.

Risks

• The blocker provision on the convertible note and pre-funded warrant limits L.I.A. Pure Capital Ltd.'s ability to fully convert or exercise if it would result in beneficial ownership exceeding 4.99% of ordinary shares.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors who acquire more than 5% of a company's stock, indicating a significant, non-controlling stake. This filing signals L.I.A. Pure Capital Ltd.'s continued interest in Clearmind Medicine Inc. as a long-term investment.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes. The presence of a significant institutional investor may be viewed positively.

Key Dates

Recommendation

The Schedule 13G filing primarily discloses a passive ownership stake by L.I.A. Pure Capital Ltd. in Clearmind Medicine Inc. While the presence of an institutional investor can be a positive signal, this filing does not contain new operational, financial, or strategic information about Clearmind Medicine Inc. that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate for existing investors, awaiting further company-specific updates.

Keywords

Clearmind Medicine Inc., L.I.A. Pure Capital Ltd., Schedule 13G, Beneficial Ownership, Common Shares, Convertible Note, Pre-funded Warrant, Institutional Investor, SEC Filing